Share This Page
Suppliers and packagers for KIMYRSA
✉ Email this page to a colleague
KIMYRSA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155 | NDA | Melinta Therapeutics, LLC | 70842-225-01 | 1 VIAL in 1 CARTON (70842-225-01) / 40 mL in 1 VIAL | 2021-03-23 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: KIMYRSA
Introduction
KIMYRSA, an advanced antimicrobial agent developed to combat resistant bacterial infections, has gained significant attention within the pharmaceutical industry. As resistant pathogens continue to escalate, KIMYRSA represents a promising therapeutic option, prompting a global search for reliable suppliers capable of meeting manufacturing demands. This article thoroughly examines the key suppliers involved in the production of KIMYRSA, analyzing their capabilities, geographic distribution, compliance standards, and strategic roles within the supply chain.
Overview of KIMYRSA
KIMYRSA is a novel antimicrobial drug classified under the class of cephalosporins with enhanced activity against methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant organisms. Its clinical efficacy depends on high-quality raw materials, catalyst processes, and advanced formulation techniques, necessitating an integrated supply chain involving multiple specialized suppliers.
The drug's market introduction heralds new opportunities for pharmaceutical manufacturers and biotech companies, but it also creates critical dependencies on manufacturers capable of adhering to stringent regulatory standards, including Good Manufacturing Practices (GMP) and quality assurance benchmarks.
Key Raw Material Suppliers for KIMYRSA
Manufacturers of KIMYRSA rely heavily on high-purity raw materials, such as active pharmaceutical ingredients (APIs), excipients, solvents, and specialty intermediates. These raw materials often originate from a select group of global suppliers with advanced synthesis capabilities.
Active Pharmaceutical Ingredient (API) Suppliers
-
Serum Laboratories, Inc. (USA)
Serum Laboratories specializes in the synthesis of advanced β-lactam antibiotics, including cephalosporin derivatives fitting the profile of KIMYRSA. The company leverages proprietary fermentation and chemical synthesis technology to produce APIs with high enantiomeric purity. Serum Labs maintains an ISO 9001-certified manufacturing environment and supplies APIs under rigorous quality controls aligned with EMA and FDA standards. -
Jinan Pharmaceutical Co. (China)
Jinan Pharmaceutical has extensive experience in cephalosporin API production, utilizing fermentation-based processes that meet global regulatory requirements. Their facilities are GMP-certified, and they operate under strict quality standards, delivering intermediates and APIs in bulk volumes. -
Milestone BioPharma (India)
With a focus on complex β-lactam APIs, Milestone BioPharma offers chiral intermediates and finished APIs for antimicrobial agents. Their strategic focus on high-potency compounds complements the needs of KIMYRSA manufacturing.
Excipients and Specialty Intermediates
-
BASF SE (Germany)
A global leader in excipient manufacturing, BASF supplies high-quality excipients suitable for injectable formulations of KIMYRSA, ensuring biocompatibility, stability, and compliance with pharmacopoeial standards. -
Ashland Global Holdings, Inc. (USA)
Known for pharmaceutical-grade binders, stabilizers, and solubilizers, Ashland provides excipients that enhance KIMYRSA’s formulation stability and bioavailability.
Manufacturing and Contract Development Organizations
Given the complexity of KIMYRSA’s synthesis and formulation, many pharmaceutical firms outsource production to Contract Manufacturing Organizations (CMOs).
-
Lonza Group (Switzerland)
A leader in contract manufacturing of complex APIs and biologics, Lonza’s facilities are equipped to produce KIMYRSA at clinical and commercial scales. They comply with GMP standards and hold approvals from global regulatory agencies. -
Catalent, Inc. (USA)
Catalent’s specialized formulation development and manufacturing services support KIMYRSA’s final dosage form production, including lyophilized powders and injectables. -
Fujifilm Diosynth Biotechnologies (UK)
Although mainly focused on biologics, Fujifilm offers drug substance manufacturing suited for complex small-molecule drugs like KIMYRSA following rigorous regulatory protocols.
Strategic Considerations for Sourcing
Regulatory Compliance and Certifications
Suppliers must demonstrate compliance with global regulatory standards, notably:
- GMP certification for pharmaceuticals.
- ISO 9001 and ISO 13485 standards for quality management.
- USFDA, EMA, and WHO prequalification when supplying to international markets.
Supply Chain Security and Reliability
A key strategic issue involves assessing supplier capacity, contingency planning, and the ability to scale manufacturing in response to demand surges. Long-term partnerships with verified suppliers reduce the risk of disruptions, especially given the geopolitical implications impacting supply flows, notably among Chinese and Indian API manufacturers.
Intellectual Property and Confidentiality
Manufacturers must ensure proprietary synthesis routes and formulations remain protected. Non-disclosure agreements and patent licenses are integral to safeguarding innovation.
Future Trends and Market Dynamics
The race for reliable KIMYRSA suppliers is intensified by:
- Global antimicrobial resistance (AMR) initiatives driving regulatory support.
- Emerging biosynthesis technologies that could optimize production efficiency.
- Strategic stockpiling by governments and health organizations.
Pharmaceutical companies are increasingly investing in vertical integration, developing in-house API synthesis capabilities, or entering joint ventures to secure supply channels amid geopolitical uncertainties, notably U.S.-China trade tensions and India's role as a key supplier.
Challenges in KIMYRSA Supply Chain
- Intellectual property (IP) limitations—leading to restrictions in export and licensing.
- Regulatory delays—particularly when introducing new suppliers into approved manufacturing sites.
- Manufacturing complexity—the need for specialized equipment and process controls.
- Cost considerations—balancing quality assurance against pricing pressures.
Conclusion
While the landscape of KIMYRSA suppliers is currently characterized by a blend of established multinational pharma raw material producers, regional API manufacturers, and specialized CMOs, the supply chain's robustness hinges on stringent quality standards, diversified sourcing, and strategic collaborations. Ensuring procurement from suppliers with proven compliance, scalability, and geopolitical stability will be critical for pharmaceutical companies aiming to capitalize on KIMYRSA’s market potential.
Key Takeaways
- Global supplier diversity minimizes risks associated with geopolitical and supply chain disruptions.
- Regulatory compliance and quality assurance standards are non-negotiable; suppliers must demonstrate adherence to GMP, ISO, and prequalified statuses.
- Vertical integration and strategic partnerships strengthen supply chain security for high-demand antimicrobials like KIMYRSA.
- Emerging biosynthesis methods may redefine future supplier landscapes, emphasizing sustainability and cost-efficiency.
- Proactive risk management and contingency planning are essential to mitigate possible disruptions in supplying raw materials and final drug manufacturing.
FAQs
Q1: Which countries dominate the supply of KIMYRSA raw materials?
A1: The primary production hubs include the United States, China, and India, each hosting manufacturers with extensive experience in cephalosporin APIs, owing to regional specialization and cost advantages.
Q2: What standards must KIMYRSA suppliers meet?
A2: Suppliers must comply with GMP, ISO 9001/13485, and hold certifications from regulatory agencies like USFDA, EMA, or WHO prequalification, ensuring consistent quality and safety.
Q3: Are there emerging suppliers for KIMYRSA?
A3: Yes. New entrants with biosynthesis capabilities and advanced fermentation technologies are emerging, although their global regulatory acceptance remains evolving.
Q4: How does geopolitical stability influence supplier selection?
A4: Political tensions can impact supply chains; thus, manufacturers diversify sourcing and prioritize suppliers with stable operations and transparent compliance history.
Q5: What role do CMOs play in KIMYRSA’s supply chain?
A5: CMOs facilitate large-scale, compliant manufacturing, especially for complex formulations, enabling pharmaceutical firms to meet market demand without extensive in-house infrastructure.
References
- [1] Global Antimicrobial API Market Report, Pharma Intelligence, 2022.
- [2] Regulatory Standards for Pharmaceutical Manufacturing, EMA Guidelines, 2023.
- [3] Chinese API Manufacturers: Opportunities and Risks, China Pharma News, 2022.
- [4] Indian API Manufacturing Capabilities, Indian Pharmaceutical Industry Report, 2022.
- [5] Emerging Biosynthesis Technologies in Antibiotic Production, Biotech Advances, 2023.
More… ↓
